LUT014, a BRAF inhibitor gel, improved acne-like rashes in patients with colorectal cancer undergoing anti-EGFR therapy, ...

The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant ...

CM24 plus Opdivo and chemo improved survival in pancreatic cancer with CEACAM1 biomarkers, supporting a biomarker-driven ...

Investigators shared real-world data showing a clear and consistent association between increased tumor size and mortality ...

Four years after remission from follicular lymphoma, ongoing fear of relapse, lingering symptoms, and life stressors continue ...

Ghoreifi works with the House Staff and is a part of Duke Urologic Oncology Fellowship, Duke Urology, at Duke School of Medicine, located in Durham, North Caroline.

Aidixi plus BCG showed strong early efficacy and manageable safety in patients with high-risk, HER2-expressing non–muscle-invasive bladder cancer.

A phase 1 trial evaluating SENTI-202 demonstrated positive preliminary results in treating relapsed/refractory acute myeloid ...

The FDA has granted approval to treatment with Tepylute, a ready-to-dilute version of thiotepa, at 100 mg for breast and ...

The Ventana TROP2 RxDx Device, a computational companion diagnostic, was granted breakthrough device designation by the FDA ...

TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk ...

TAR-200 showed high complete response rates in BCG-unresponsive, high-risk non-muscle invasive bladder cancer with CIS in the ...